Introduction
============

Renal cell carcinoma is the most common lethal tumor of all the urological neoplasms [@B1]. There is a total of 209,000 new cases and 102,000 deaths per year worldwide, with the male-to-female ratio being 1.5:1.0, with peaks at age 60-70 years [@B2]. The specific causes of RCC are still unknown, but epidemiological studies have reported that many factors, like smoking tobacco, hypertension, kidney diseases, diabetes, obesity, and genetics, could increase the risk of RCC [@B3]-[@B5].

The single-nucleotide polymorphism (SNP) is the simplest form of DNA variation among individuals. Some SNPs in coding regions change the amino acid sequence of a protein, and others in the coding region do not affect the protein sequence. SNPs outside the coding region may also affect transcription factor binding, gene splicing, or mRNA degradation [@B6]. Many studies have reported that SNPs can act as genetic markers to identify the complete set of genes that are involved in the development of renal cancer. For example, two genetic susceptibility loci, rs4415084 and rs10941679, at chromosome 5p12 are associated with breast cancer risk [@B7], while two SNPs significantly associated with miRNA expression levels, rs8176318 (BRCA1) and rs8905 (PRKAR1A), are associated with colon cancer risk [@B8].

Melanoma antigen-A11 (*MAGE-A11*) belongs to the *MAGE-A* subfamily of cancer-germline antigens at the Xq28 locus of the human X chromosome [@B9]. *MAGE-A11*, which specifically binds to the human androgen receptor (AR) N-terminal FXXLF motif and functions as an AR coregulator that increases transcriptional activity of AR, competing with the AR N/C interaction and exposing the activation function 2 site in the ligand binding domain [@B10]. *MAGE-A11* has a low expression level in normal human testis, ovary, and placenta, while it is upregulated during prostate cancer progression due to hypomethylation of the *MAGE-A11* promoter and increasing cyclic AMP levels, associated with increased AR transcriptional activity [@B11], [@B12]. Our previous study also found that *MAGE-A11* and AR cooperated in the upregulation of FSTL1 to promote growth and progression of castration-resistant/recurrent prostate cancer [@B13]. However, to the best of our knowledge, the role of *MAGE-A11* in RCC has not been reported.

In this study, we selected two common SNPs of the *MAGE-A11* gene (i.e., S1.rs6641352 T\>C and S2.rs6540341 C\>T) to evaluate their associations with the risk and survival of RCC by a two-stage case control study and a cohort study. Further analyses were conducted to determine the effects of SNPs on RCC and survival.

Materials and methods
=====================

Selection and characteristics of patients
-----------------------------------------

The project was approved by the Institutional Review Board of the Nanjing Medical University. Each participant involved in this study signed a written informed consent prior to inclusion in the study. A total of 1027 cases and 1094 controls were collected from May 2004 to March 2014 at the First Affiliated Hospital of Nanjing Medical University. The inclusion criteria have been described previously [@B14], [@B15]: (1) The cases were newly diagnosed with incident RCC. (2) The cases had been histopathologically confirmed. (3) The cases did not have a prior history of other malignancies. (4) The cases have not been treated with chemotherapy or radiotherapy. (5) The cases have complete treatment and follow-up information. The controls were recruited from subjects without any individual history of cancer who were seeking health care in the outpatient departments at the hospital and were frequency matched to the cases for sex and age (±5 years). In this cohort, 17 patients and 140 controls were excluded due to low DNA concentrations or because of incomplete data. Each patient\'s RCC classification and stage were determined according to the TNM staging system by the American Joint Committee on Cancer (AJCC). The validation cohort was made up sampling randomly 500 cases and 470 controls from subjects conforming the inclusion criteria the by IBM SPSS 24.0. All enrolled patients were frequency-matched for age (±5 years) and sex. For the survival analysis, 355 patients were followed up prospectively for overall survival information every 6 months from the histological confirmation until death or the last follow-up. Of them, 47 patients were excluded due to low DNA concentrations or a lack of complete follow-up information.

SNP selection and genotyping
----------------------------

We identified potentially functional polymorphisms according to the following criteria: (1) located in the 5′ flanking region, the 5′ untranslated region (UTR), the 3′-UTR, or the coding region causing an amino acid change; (2) minor allele frequency (MAF) \> 0.05 in the CHB and JPT population from the 1000 Genomes Project; (3) *r^2^* \> 0.8 based on the pairwise linkage disequilibrium using Haploview version 4.2. Two polymorphisms in *MAGE-A11* (rs6641352 and rs6540341) were selected for further analysis and processing. Genotyping was performed using the TaqMan SNP genotyping method, as previously described [@B14].

Statistical analysis
--------------------

Differences in the distribution of selected demographic variables between RCC cases and cancer-free controls were evaluated using the Student *t* test for continuous variables and Pearson\'s χ^2^ test or Fisher\'s exact test for categorical variables. The Hardy-Weinberg equilibrium for all SNP allele frequencies among controls was tested using a goodness-of-fit χ^2^ test. The associations between SNPs and RCC susceptibility were estimated by computing odds ratios and 95% confidence intervals (CIs) from unconditional logistic regression analyses. Bonferroni correction was applied for multiple comparison. Four genetic models (additive, dominant, recessive, and codominant) were used to assess the effects of SNPs. The heterogeneity between subgroups was estimated with the χ^2^ based on the Q-test. The survival time curves were estimated using the Kaplan-Meier method, and comparisons were made by the log-rank test. Survival time was calculated from the date of RCC diagnosis to the date of death or the last follow-up. Cox proportional hazard models were used to calculate hazard ratios and 95% CIs for predicting factors of RCC survival. A *P*-value \<0.05 is considered statistically significant. All statistical analyses were performed by IBM SPSS 24.0. The survival plot was performed by GraphPad Prism 7.

Results
=======

Characteristics of study population
-----------------------------------

The demographic characteristics and clinical features of RCC patients and controls in totality and validation set are listed in Table [1](#T1){ref-type="table"} and S1, respectively. No significant differences were found among patients and controls in terms of age, body mass index, gender, smoking status, drinking status, and family history of cancer (all *P* \> 0.05). However, more hypertension and diabetes were observed in patients than in controls (both *P* \< 0.001), suggesting that hypertension and diabetes may contribute to RCC development.

Associations between the MAGE-A11 SNPs and RCC risk
---------------------------------------------------

The characteristics of the selected SNPs are presented in Table [2](#T2){ref-type="table"}. All genotype frequencies of SNPs conformed to the Hardy-Weinberg equilibrium (0.472 and 0.467, respectively). As shown in Table [3](#T3){ref-type="table"}, both selected SNPs were significantly associated with RCC risk. For rs6641352 in the gene*MAGE-A11*, individuals with the C allele had a higher risk of tumorigenesis (odds ratio = 1.315, 95% CI = 1.089-1.588, *P* = 0.004 in the dominant model). Significant associations were also observed in the additive model (odds ratio = 1.250, 95% CI = 1.069-1.461, *P* = 0.005), even after the Bonferroni correction (*P* = 0.020). However, the significance of rs6641352 disappeared in the validation set after Bonferroni correction (*P* = 0.068). No obvious significance was found in the recessive model (*P* = 0.220).

Upon our stratified analysis of individual characteristics and clinicopathological features (Tables S2 and S3), we detected a pathogenic effect of the rs6641352 C allele among subjects with lower age and body mass index (BMI), with smoking and hypertension, without drinking, diabetes, and a family history of cancer, and among the male and patients in an early stage (all *P* \< 0.02). However, there was no association between the rs6641352 genotype and clinical features (Table [S4](#SM0){ref-type="supplementary-material"}).

For the SNP rs6540341, a similar effect on kidney tumorigenesis was found. As shown in Table [3](#T3){ref-type="table"}, the genotypes CT/TT could increase the risk of RCC occurrence compared with the homozygous CC genotype (odds ratio = 1.301, 95% CI = 1.081-1.564, *P* \< 0.001 in the dominant model), which was confirmed by the validation set(odds ratio = 1.317, 95% CI = 1.014-1.711, *P* = 0.039). We further conducted the stratified analysis and found a negative effect of the rs6540341 T allele among those with lower age and higher body mass index, without drinking, hypertension, and family history of cancer and among the females. The same consequence was observed among patients at an early stage and grade and pathologically diagnosed with RCC (all *P* ≤ 0.05; Tables S5 and S6). However, there was no association between the rs6540341 genotype and clinical features (Table [S7](#SM0){ref-type="supplementary-material"}).

Effects of two SNPs on RCC survival
-----------------------------------

To explore the effects of the two SNPs on RCC survival, we analyzed clinical follow-up data of 308 RCC patients. The average follow-up time was 14.9 months (ranging from 0.63 to 72 months). For rs6641352, as shown in Table [3](#T3){ref-type="table"} and Figure [1](#F1){ref-type="fig"}, no patients with the rare homozygous CC genotype lived to 5 years, suggesting a poorer prognosis compared with those with the T allele (hazard ratio = 3.526, 95% CI = 1.072-11.595; log-rank *P* \< 0.001), especially in stage I/II (log-rank *P* \< 0.001). The results of the advanced stage are questionable due to the small sample size.

The characteristics and clinical features of RCC patients are listed in Table [S8](#SM0){ref-type="supplementary-material"}. Due to the fact that the small number of individuals with rs6641352CC is further reduced in the stratified analysis, which may cause unstable associations, we will not discuss the stratified analysis of *MAGE-A11* rs6641352, though the results are presented in Table [S9](#SM0){ref-type="supplementary-material"}. Stepwise Cox proportional hazard analysis was carried out for further analysis (Table [S10](#SM0){ref-type="supplementary-material"}); seven variables, including rs6641352 in the recessive model, were retained in the regression model, indicating that rs6641352 may be an independent prognosis factor. For rs6540341, there was no association observed in either of the four genetic models (Table [S11](#SM0){ref-type="supplementary-material"}).

Discussion
==========

In a previous study, we found that in prostate cancer, *MAGE-A11* is a proto-oncogene, the increased expression of which reverses retinoblastoma-related protein p107 from a transcriptional repressor to a transcriptional activator of the AR and E2F1 [@B16]. *MAGE-A11* is a cancer-testis antigen of the*MAGE-A* gene family, notable for its increased expression in cancer [@B2], [@B9], [@B17]. Many carcinomas, like breast cancer [@B18], [@B19], head and neck carcinomas [@B20], and laryngeal squamous cell carcinoma [@B21], have been associated with *MAGE-A11*. However, the role of *MAGE-A11* in RCC has not been reported.

In this study, we evaluated the associations between two SNPs in *MAGE-A11* and RCC susceptibility and prognosis. We found that*MAGE-A11* rs6641352 and rs6540341 are associated with an increased risk of RCC. We also observed a negative impact of rs6641352 on RCC survival, while rs6540341 seemed irrelevant to prognosis.

As regards rs6641352, we observed that the TC/CC genotypes significantly increased the risk of RCC, the heterozygous genotype TC more so than the CC genotype. Further stratification analyses suggested that the association between rs6641352 and the increased RCC risk was more prominent in males, smokers, and hyperpietics, which agrees with epidemiology statistics [@B3]-[@B5]. Unexpectedly, subjects without drinking history, diabetes, and family history of cancer showed a stronger susceptibility to RCC. In addition, the CC genotype (vs. TC/TT) of rs6641352 showed a 3.526-fold increased hazard ratio for RCC survival, independently predicting an unfavorable postoperative prognosis in RCC, while we did not obtain statistically significant results for the different alleles of rs6540341.

For rs6540341, all four models showed a strongly increased risk of RCC; especially when considering the additive model or the recessive model, we could hypothesize that the C allele of rs6540341 plays a critical role in renal carcinogenesis. Moreover, the stratification analyses showed a higher risk of RCC among the younger, the obese, and the females, as well as those without hypertension, drinking history, or family history of cancer. The stratification analyses on rs6641352 implied that there may be an interaction between the SNPs and the risk of developing RCC.

The roles of intronic SNPs in tumor formation have received more and more attention in recent years. The intronic SNPs are involved in gene regulation via an intronic enhancer, by regulating expression levels, or by other regulatory modifications [@B22], [@B23]. As rs6641352 and rs6540341 are intronic SNPs based on genome browser data (<http://genome.ucsc.edu>; data not shown), they may be passengers rather than drivers in the tumorigenesis of RCC. Both of them are not localized in the predicted regulatory regions of *MAGE-A11*.

In conclusion, this is the first study to explore the epidemiological evidence on *MAGE-A11* SNPs and their statistic relationships with RCC and overall survival rate in the Chinese population. We identified two new loci that are associated with RCC occurrence, *MAGE-A11* rs6641352 and rs6540341, while rs6641352 could also predict RCC patients\' survival. However, the data for survival analysis are not sufficient, and the study is lacking an independent cohort for validation. The underlying mechanism by which the two *MAGE-A11* SNPs cause RCC morbidity is still unknown. Further *in vitro* and *in vivo* research is required.
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###### 

Demographic characteristic and clinical features among RCC case patients and control subjects.

  ---------------------------------------------------------------------------------------
  Characteristics            Number of cases (%)   Number of controls (%)   *P*^a^
  -------------------------- --------------------- ------------------------ -------------
  Overall\                   1010\                 954\                     0.109
  Age (years) (mean ± SD)    56.72 ± 12.08         55.86 ± 11.61            

  BMI (kg/m2) (mean ± SD)    24.07 ± 2.91          23.82 ± 3.27             0.074

  Gender                                                                    0.093

  Male                       640 (63.4)            639 (67.0)               

  Female                     370 (36.6)            315 (33.0)               

  Smoking status                                                            0.077

  Never                      638 (63.2)            639 (67.0)               

  Ever                       372 (36.8)            315 (33.0)               

  Drinking status                                                           0.830

  Never                      741 (73.4)            704 (73.8)               

  Ever                       269 (26.6)            250 (26.2)               

  **Hypertension**                                                          **\<0.001**

  No                         620 (61.4)            886 (92.9)               

  Yes                        390 (38.6)            68 (7.1)                 

  **Diabetes**                                                              **\<0.001**

  No                         879 (87.0)            896 (93.9)               

  Yes                        131 (13.0)            58 (6.1)                 

  Family history of cancer                                                  0.602

  No                         944 (93.5)            886 (92.9)               

  Yes                        66 (6.5)              68 (7.1)                 

  Clinical stage                                                            

  Ⅰ                          221 (21.9)                                     

  Ⅱ                          514 (50.9)                                     

  Ⅲ                          211 (20.9)                                     

  Ⅳ                          64 (6.3)                                       

  Tumor grade                                                               

  Ⅰ                          658 (65.1)                                     

  Ⅱ                          198 (19.6)                                     

  Ⅲ                          73 (7.2)                                       

  Ⅳ                          81 (8.0)                                       

  Histology                                                                 

  Clear cell                 843 (83.5)                                     

  Papillary                  36 (3.6)                                       

  Chromophobe                55 (5.4)                                       

  Unclassified               76 (7.5)                                       
  ---------------------------------------------------------------------------------------

^a^Student\'s t-test for age and BMI distributions between cases and controls;

χ2-test of R-by-C table for other selected variables between cases and controls.

###### 

Demographic characteristic of 2 SNPs in *MAGE-A11* gene.

  SNPs        Alleles (major/minor)   Cases^a^ (n=1010)   Contorls^a^ (n=954)      Location   MAF^b^ (Case/Control)   Call rate (%)   HWE^c^
  ----------- ----------------------- ------------------- --------------------- -- ---------- ----------------------- --------------- --------
  rs6641352   T/C                     596/357/57          625/287/42               3\'-UTR    0.233/0.194             98.9            0.472
  rs6540341   C/T                     561/359/90          586/315/53               3\'-UTR    0.267/0.221             98.9            0.467

^a^ Major homozygote/heterozygote/minor homozygote between cases and controls.

^b^ MAF (minor allele frequency) between case and control group.

^c^ HWE (Hardy-Weinberg equilibrium) test among controls.

###### 

Association of the 2 SNPs in *MAGE-A11* gene and risk of RCC in totality and validation set.

  Stages       SNPs        OR (95% CI)^a^            P^b^                      Bonferroni^c^                                                                             
  ------------ ----------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ----------- -----------
  Totality     rs6641352   **1.250 (1.069-1.461)**   **1.315 (1.089-1.588)**   1.299 (0.855-1.975)       **1.299 (1.066-1.583)**   1.423 (0.931-2.174)       **0.005**   **0.020**
               rs6540341   **1.275 (1.102-1.476)**   **1.301 (1.081-1.564)**   **1.614 (1.123-2.320)**   **1.226 (1.009-1.491)**   **1.740 (1.202-2.519)**   **0.001**   **0.004**
  Validation   rs6641352   **1.309 (1.049-1.633)**   **1.456 (1.113-1.905)**   1.112 (0.618-2.001)       **1.489 (1.123-1.974)**   1.269 (0.700-2.302)       **0.017**   0.068
               rs6540341   **1.298 (1.056-1.596)**   **1.317 (1.014-1.711)**   **1.717 (1.030-2.862)**   1.228 (0.931-1.619)       **1.852 (1.100-3.120)**   **0.013**   0.052

Values in bold indicate are statistically different.

^a^Logistic regression model with adjustment for age, sex, BMI, smoking status, drinking status, hypertension, diabetes and family history of cancer in additive (rare homozygote versus heterozygote versus major homozygote) models, dominant (heterozygote/rare homozygote versus major homozygote), recessive (rare homozygote versus heterozygote/major homozygote) and codominant (het: heterozygote versus major homozygote; hom: rare homozygote versus major homozygote). BMI, body mass index; OR, odds ratio.

^b^Adjusted for age, sex, BMI, smoking status, drinking status, hypertension, diabetes and family history of cancer in additive model

^c^Bonferroni correction for additive model.

###### 

Associations between the 2 SNPs in *MAGE-A11* gene and RCC patients\' survival.

  rs6641352 (T/C)            Patients/deaths   5-year survival (%)^a^   Log-rank P    Crude HR (95% CI)          HR (95% CI)^b^             P^b^
  -------------------------- ----------------- ------------------------ ------------- -------------------------- -------------------------- -----------
  Total number of subjects   308/32            80                                                                                           
  Codominant model                                                                                                                          
  TT                         191/17            81                                     1.000 (reference)          1.000 (reference)          
  TC                         104/9             86                       0.554         0.803 (0.353-1.823)        0.753 (0.291-1.953)        0.560
  CC                         13/6              ------                   **0.001**     **4.193 (1.635-10.757)**   3.217 (0.940-11.013)       0.063
  P trend                                                               0.079                                                               
  Additive model                                                        **0.001**     1.625 (0.940-2.809)        1.415 (0.773-2.592)        0.261
  Dominant model                                                                                                                            
  TT                         191/17            81                                     1.000 (reference)          1.000 (reference)          
  TC/CC                      117/15            79                       0.653         0.636 (0.584-2.410)        1.110 (0.488-2.523)        0.804
  Recessive model                                                                                                                           
  TT/TC                      295/26            83                                     1.000 (reference)          1.000 (reference)          
  CC                         13/6              ------                   **\<0.001**   **4.569 (1.870-11.161)**   **3.526 (1.072-11.595)**   **0.038**

BMI, body mass index; HR, hazard ratio.

Values in bold indicate statistically different.

^a^Proportion of survival derived from Kaplan-Meier analysis.

^b^Adjusted for age, sex, BMI, smoking status, drinking status, hypertension, diabetes and family history of cancer, clinical stage, tumor stage and histology in Cox regression model.
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